Key Points
- William Guyer sold 20,000 shares on May 5 at an average price of $51.83 for a $1,036,600 transaction, cutting his stake by about 89.96% to 2,231 shares, according to the SEC filing.
- Corcept missed Q1 estimates, reporting EPS of -$0.30 versus a consensus of -$0.11 and revenue of $164.9M versus an expected $185.8M, a near-term negative for the stock.
- Despite the miss, analysts turned more positive—HC Wainwright raised its target to $75 and several firms upgraded ratings—and institutional ownership remains high at 93.61%, signaling strong institutional interest.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 20,000 shares of the firm's stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $51.83, for a total transaction of $1,036,600.00. Following the completion of the transaction, the insider directly owned 2,231 shares of the company's stock, valued at approximately $115,632.73. This trade represents a 89.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
William Guyer also recently made the following trade(s):
- On Tuesday, April 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $40.97, for a total transaction of $819,400.00.
- On Friday, March 20th, William Guyer sold 11,767 shares of Corcept Therapeutics stock. The shares were sold at an average price of $36.01, for a total transaction of $423,729.67.
- On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The shares were sold at an average price of $35.99, for a total transaction of $296,305.67.
Corcept Therapeutics Trading Down 2.1%
Corcept Therapeutics stock opened at $51.05 on Friday. The company has a market cap of $5.48 billion, a P/E ratio of 145.86 and a beta of 0.36. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $91.00. The company has a fifty day simple moving average of $40.09 and a 200 day simple moving average of $53.80.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm had revenue of $164.90 million during the quarter, compared to the consensus estimate of $185.83 million. During the same period last year, the business earned $0.17 EPS. The business's revenue was up 4.9% on a year-over-year basis. On average, equities research analysts forecast that Corcept Therapeutics Incorporated will post 0.48 EPS for the current year.
More Corcept Therapeutics News
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: HC Wainwright sharply raised multi-year earnings forecasts and increased near-term EPS estimates (including Q2/FY2026 and FY2027–FY2030), maintaining a "Buy" rating and a $75 price target — a major bullish analyst signal that supports higher valuation expectations.
- Positive Sentiment: Market reaction to Corcept's Q1 update: although the quarter showed a loss, analysts and investors focused on management's stronger 2026 outlook and new ALS-related data, which helped lift the stock earlier in the day. Article Title
- Positive Sentiment: Zacks Research upgraded CORT from "strong sell" to "hold," a modestly positive change in sell-side sentiment that can reduce selling pressure. Zacks Research
- Neutral Sentiment: Q1 2026 earnings call transcript is available for investors parsing management commentary and forward guidance for signs of durable revenue growth or margin improvement. Earnings Call Transcript
- Negative Sentiment: Insider selling: William Guyer sold 20,000 shares at an average $51.83 on May 5, materially reducing his position (about a 90% cut), which can be read negatively by some investors. SEC filing: SEC Filing
- Negative Sentiment: Q1 results missed consensus on EPS and revenue came in below estimates — a near-term negative that likely contributed to volatile price action despite the upbeat outlook. (This is the earnings backdrop that makes today's analyst upgrades and data releases pivotal.)
Analyst Ratings Changes
A number of research analysts have recently commented on CORT shares. HC Wainwright lifted their price objective on shares of Corcept Therapeutics from $60.00 to $75.00 and gave the company a "buy" rating in a research report on Monday. Zacks Research raised shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday. Truist Financial raised shares of Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday, March 25th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Thursday, March 26th. Finally, Piper Sandler lifted their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $74.67.
Read Our Latest Stock Analysis on CORT
Institutional Trading of Corcept Therapeutics
A number of hedge funds have recently modified their holdings of CORT. AQR Capital Management LLC lifted its stake in shares of Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company's stock worth $125,264,000 after buying an additional 1,274,215 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company's stock worth $92,892,000 after buying an additional 734,646 shares during the last quarter. Norges Bank acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $24,213,000. JPMorgan Chase & Co. lifted its stake in shares of Corcept Therapeutics by 223.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company's stock worth $70,632,000 after buying an additional 587,053 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of Corcept Therapeutics by 413.8% during the 3rd quarter. UBS Group AG now owns 549,938 shares of the biotechnology company's stock worth $45,705,000 after buying an additional 442,898 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company's stock.
Corcept Therapeutics Company Profile
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
